Pay in 4 interest-free payments of $5.14 Learn more
Ships within 48 hours · Estimated delivery Sep 1 - Sep 6
conserva en lugar fresco y seco y consulta siempre a un profesional sanitario
Obesity drug tirzepatide approval in China strengthens market position amid GLP-1 agonist competition: GlobalData Benemaes benaglutide injection (Feisumei) was the first innovator approved for obesity in July 2023 in China followed by Novo Nordisks diabetes therapy semaglutide (Wegovy) in June 2024 Eli Lillys tirzepatide (Mounjaro) has recently been approved by the National Medical Products Administration (NMPA) for treating obesity
Losing visceral fat reduces estrogen conversion, improves insulin sensitivity, and lowers inflammation, all of which support healthier testosterone production
A balanced macronutrient distribution following US Dietary Reference Intakes (carbohydrates 4565%, protein 1035%, and fats 2035%) supports satiety and metabolic health
US$ 27.85
US$ 21.28
US$ 27.96
